Harvest Portfolios Group Inc. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Harvest Portfolios Group Inc. increased its stake in Regeneron Pharmaceuticals by 16.2% during the 1st quarter, now holding 82,924 shares valued at approximately $52.6 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly exceeding analysts' expectations of $8.43.
• The company recently declared a quarterly dividend of $0.88 per share, translating to an annualized total of $3.52 and a dividend yield of 0.6%.

Harvest Portfolios Group Inc. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,924 shares of the biopharmaceutical company's stock after purchasing an additional 11,555 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.6% of Harvest Portfolios Group Inc.'s portfolio, making the stock its 20th largest position. Harvest Portfolios Group Inc. owned about 0.08% of Regeneron Pharmaceuticals worth $52,593,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Citigroup reiterated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $7.35 on Thursday, reaching $579.61. The company had a trading volume of 616,549 shares, compared to its average volume of 1,082,231. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $61.43 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33. The firm's 50 day moving average price is $555.84 and its 200 day moving average price is $588.67. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,210.97.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $11.56 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.